Kailera Therapeutics

NEWS

Robotic claw clutching a money stock illustration

Series B

Kailera Banks Massive $600M Raise for Phase III Obesity Study

Kailera’s lead asset, KAI-9531, elicited an average weight loss of more than 17% in a Phase III study in China. The biotech expects to launch a global late-stage program for the drug this year.

October 14, 2025

2 min read

Tristan Manalac

Weigh scales on pink background, top view with space for text. Overweight concept

GLP-1

Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera Therapeutics outlining their plans in the space moving forward.

January 14, 2025

2 min read

Tristan Manalac

Fashionable halftone collage. Concept of wealth, saving, saving and saving money. Money bag with dollar stacks and stacks of coins. Vector illustration of business and finance for web banner, social media banner, marketing material. Vector illustration

Weight loss

Kailera Launches With $400M to Advance China-Developed Obesity Assets

Venture Capital firms Atlas Venture, Bain Capital Life Sciences and RTW Investments have led a $400 million Series A for Kailera Therapeutics, the latest obesity biotech to hit the scene.

October 1, 2024

1 min read

Annalee Armstrong

IN THE PRESS

Press Releases

Kailera Therapeutics to Participate in Upcoming November 2025 Investor Conferences

November 6, 2025

1 min read

Press Releases

Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531

November 5, 2025

7 min read